( March 18, 2026, 2:42 PM EDT) -- SAN FRANCISCO — The Ninth Circuit U.S. Court of Appeals on March 17 reversed and remanded a lower court’s dismissal of a health system’s qui tam suit asserting violations of the False Claims Act (FCA) and related state laws by drug manufacturers participating in the Public Health Service Act’s Section 340B Drug Pricing Program, finding that because the health system brought an action pursuant to the FCA, the lack of a private right of action under Section 340B was not material and therefore the health system’s claims were not barred by Section 340B....